Co-GP / Platform:A family office could deploy into the life sciences market by backing a sponsor/operator at the GP level to share in the promote and capitalize on emerging opportunities.

Co-GP / Platform:A family office could deploy into the life sciences market by backing a sponsor or operator at the GP level to capitalize on the improving vacancy landscape.

Co-GP / Platform:A family office could deploy into the life sciences market by backing a sponsor or operator at the GP level, focusing on co-GP or JV equity to share in the promote.

Co-GP / Platform:A family office could deploy into the life sciences market by backing a sponsor/operator at the GP level, focusing on those with a proven track record in managing life science assets.

Co-GP / Platform:A family office could deploy into this life sciences market by backing a sponsor or operator at the GP level, focusing on emerging markets like Raleigh-Durham and Northern New Jersey.

Co-GP / Platform:A family office could deploy into the life sciences market by backing a sponsor or operator at the GP level, sharing in the promote and aligning interests amid funding uncertainties.

Co-GP / Platform:A family office could deploy into the life sciences market by backing a sponsor/operator at the GP level, focusing on those developing specialized lab spaces in key markets like Boston-Cambridge or New York.

Co-GP / Platform:A family office could deploy into the life sciences market by backing a sponsor or operator at the GP level to share in the promote and benefit from a repeatable pipeline.

Co-GP / Platform:A family office could deploy into this market by backing a life sciences operator at the GP level, sharing in the promote and aligning interests as developers offload assets.

Co-GP / Platform:A family office could deploy into the life sciences market by backing a sponsor/operator at the GP level, focusing on those with a strong development pipeline in key markets like Boston-Cambridge or San Francisco.

Co-GP / Platform:A family office could deploy into the life sciences market by backing a sponsor/operator at the GP level, focusing on those with a proven track record in managing new developments.

Co-GP / Platform:A family office could deploy into the life sciences market by backing a sponsor/operator focused on developing lab spaces to capitalize on the growing demand for flexible, pre-built environments.

Co-GP / Platform:A family office could deploy into the life sciences market by backing a sponsor or operator at the GP level, focusing on those with a strong track record in navigating tenant requirements.

Co-GP / Platform:A family office could deploy into the life sciences market by backing a sponsor or operator at the GP level, sharing in the promote and benefiting from their expertise.

Co-GP / Platform:A family office could deploy into the life sciences market by backing a sponsor or operator at the GP level to share in the promote and benefit from a recovering sector.

Co-GP / Platform:A family office could deploy into the life sciences market by co-investing with sponsors like Alexandria Real Estate, which is expanding its lab projects.

Co-GP / Platform:A family office could deploy into the life science market by backing a sponsor with a strong capital base, ensuring alignment and shared success in navigating tenant demands.

Co-GP / Platform:A family office could deploy into the life sciences market by backing a sponsor/operator at the GP level, focusing on co-GP or JV equity to share in the promote and enterprise value.